Form 4: EyePoint Pharmaceuticals Director Stuart Duty Acquires 40,000 Stock Options
SEC Form 4
Director Stuart Duty acquired 40,000 stock options in EyePoint Pharmaceuticals on January 3, 2025.
Summary
- On January 3, 2025, Stuart Duty, a director of EyePoint Pharmaceuticals, acquired 40,000 stock options.
- The exercise price of these options is $8.26.
- The options become exercisable on January 3, 2026, and expire on January 3, 2035.
- Following the transaction, Duty directly owns 40,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Stuart Duty acquired 40,000 stock options. |
| 01/03/2026 | Date exercisable: Stock options become exercisable. |
| 01/03/2035 | Expiration date: Stock options expire. |
| 01/07/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.